{"id":"W4399481376","doi":"10.1136/annrheumdis-2024-eular.250","title":"POS0527 DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): EFFICACY BY BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN THE PHASE 2 PAISLEY TRIAL","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Demographics; Systemic lupus erythematosus; Internal medicine; Pharmacology; Disease; Oncology; Demography","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008537385,0.0009977848,0.00144,0.0002086607,0.0002177038,0.000785405,0.0004286659,0.0005784318,0.002716667],"category_scores_gemma":[0.0005370498,0.0002168678,0.0009923625,0.0002812953,0.0004853825,0.0007855982,0.0001979206,0.001871025,0.000620424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006916868,"about_ca_system_score_gemma":0.0005977739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005860034,"about_ca_topic_score_gemma":0.002689117,"domain_scores_codex":[0.9997422,0.0001013048,0.00001318227,0.00004301075,0.00002754978,0.00007275823],"domain_scores_gemma":[0.9997484,0.00005887527,0.00004493996,0.00001554611,0.00001368812,0.0001184978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6642925,0.005056172,0.01640275,0.00190818,0.003601321,0.0003365922,0.0002310437,0.005248406,0.02199533,0.001251427,0.016936,0.2627404],"study_design_scores_gemma":[0.6778877,0.2200782,0.06776851,0.0002683594,0.002311117,0.001304273,0.000238294,0.005478566,0.004787063,0.001385745,0.01836726,0.0001249683],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843731,0.01009877,0.0002465086,0.000462622,0.0001732127,0.0002136353,0.001043735,0.0001196018,0.003268825],"genre_scores_gemma":[0.9914461,0.003284408,0.0002986049,0.0005320939,0.0001122397,0.0002226496,0.001838776,0.00001773677,0.002247419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002716667,"threshold_uncertainty_score":0.009088159,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03300773911830283,"score_gpt":0.3178285190322137,"score_spread":0.2848207799139108,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}